Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is >= 10%?

E. Merola; Alonso T. Gordoa; P. Zhang; T. Al-Toubah; E. Pelle; M. Liu; F. Laskaratos; L. de Mestier; A. Lamarca; J. Hernando; M. Cives; R. van Leeuwaarde

Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is >= 10%?

E. Merola
, Alonso T. Gordoa
, P. Zhang
, T. Al-Toubah
, E. Pelle
, M. Liu
, F. Laskaratos
, L. de Mestier
, A. Lamarca
, J. Hernando
, M. Cives
, R. van Leeuwaarde

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	197-197
Journal	Neuroendocrinology
Volume	110
Publication status	Published - Mar 2020

Keywords

pancreatic net
somatostatin analogs
grade 2 and 3
safety
efficacy

Cite this

@article{06a3ae22a9364d03a0592c9d90ec3a1f,

title = "Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is >= 10\%?",

keywords = "pancreatic net, somatostatin analogs, grade 2 and 3, safety, efficacy",

author = "E. Merola and Gordoa, \{Alonso T.\} and P. Zhang and T. Al-Toubah and E. Pelle and M. Liu and F. Laskaratos and \{de Mestier\}, L. and A. Lamarca and J. Hernando and M. Cives and \{van Leeuwaarde\}, R.",

year = "2020",

month = mar,

language = "English",

volume = "110",

pages = "197--197",

journal = "Neuroendocrinology",